Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Cash-to-Debt

: 0.44 (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shanghai Fosun Pharmaceutical (Group) Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.44.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Shanghai Fosun Pharmaceutical (Group) Co couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt or its related term are showing as below:

SHSE:600196' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: 0.47 Max: 0.6
Current: 0.44

During the past 13 years, Shanghai Fosun Pharmaceutical (Group) Co's highest Cash to Debt Ratio was 0.60. The lowest was 0.37. And the median was 0.47.

SHSE:600196's Cash-to-Debt is ranked worse than
63.61% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs SHSE:600196: 0.44

Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.46

0.50

0.60

0.57

0.44

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.57	0.52	0.51	0.47	0.44

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt falls into.

Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Shanghai Fosun Pharmaceutical (Group) Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15582.087	/	(19555.051	+	15554.512)
	=	0.44

Shanghai Fosun Pharmaceutical (Group) Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15582.087	/	(19555.051	+	15554.512)
	=	0.44

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Shanghai Fosun Pharmaceutical (Group) Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » Cash-to-Debt

Traded in Other Exchanges

SFOSF:USA 02196:Hong Kong 08HH:Germany

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Headlines

No Headlines